Screener
Ultragenyx Pharmaceutical RARE Total debt
Discontinued — last reported Q4 '25
Total debt at other companies
Other financials
Where this comes from
Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $36M.
The source filing: Ultragenyx Pharmaceutical’s 10-K, filed February 18, 2026. Open the filing →
- Filed
- Feb 18, 2026, 4:59 PM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-057329
FAQ
- What is Ultragenyx Pharmaceutical's total debt?
- Ultragenyx Pharmaceutical (RARE) reported total debt of $36M in Q4 2025.
- How has Ultragenyx Pharmaceutical's total debt changed year-over-year?
- Ultragenyx Pharmaceutical's total debt decreased by 10.8% year-over-year, from $40.34M to $36M.
- What is the long-term trend for Ultragenyx Pharmaceutical's total debt?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's total debt has grown at a -5.7% compound annual growth rate (CAGR), from $48.23M to $36M.
- What does total debt mean?
- Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.
Ask your AI about Ultragenyx Pharmaceutical's total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude